Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1CNS 1

Conditions

Breast Neoplasms 145Lymphoma 104Lymphoma, Large B-Cell, Diffuse 76Sarcoma 62Hodgkin Disease 46Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Burkitt Lymphoma 35Triple Negative Breast Neoplasms 31Lymphoma, Non-Hodgkin 29Lymphoma, Mantle-Cell 27Leukemia 25Neoplasms 22Lymphoma, Follicular 22Neoplasm Metastasis 21Multiple Myeloma 21Neuroblastoma 20Carcinoma, Hepatocellular 18Ovarian Neoplasms 16Lymphoma, B-Cell 16Liver Neoplasms 14Urinary Bladder Neoplasms 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Osteosarcoma 12Lymphoma, T-Cell, Peripheral 11Lymphoma, Large-Cell, Anaplastic 11Inflammatory Breast Neoplasms 11Breast Neoplasms, Male 11Prostatic Neoplasms 10Dendritic Cell Sarcoma, Interdigitating 10Lymphoma, Large-Cell, Immunoblastic 9

Interventions

Filgrastim 3Etoposide 3Cisplatin 3Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2sargramostim 1etoposide phosphate 1enasidenib 1apatinib 1aldesleukin 1Tomography, X-Ray Computed 1Thiotepa 1Ritonavir 1Radionuclide Imaging 1Positron-Emission Tomography 1Paclitaxel 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Indinavir 1Ifosfamide 1Ibuprofen 1Gemcitabine 1Endoscopic Mucosal Resection 1Electrocardiography 1Doxorubicin 1Docetaxel 1Cyclophosphamide 1Chemotherapy, Adjuvant 1Carmustine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Esthesioneuroblastoma, Olfactory × Doxorubicin × Clear all
NCT00509665 2018-07-12

Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer

Medical University of South Carolina

Phase 2 Completed
18 enrolled 9 charts
CNSHead & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Salivary Gland Neoplasms, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡